Diltiazem for Tenesmus: Off-Label Use with Limited Evidence
Diltiazem can be considered as an adjunct therapy for malignancy-associated rectal tenesmus, particularly when characterized by pressure-type pain, though this represents an off-label use with only case series evidence to support it.
Evidence Base and Mechanism
The use of diltiazem for tenesmus is not supported by FDA-approved indications—diltiazem is officially indicated only for chronic stable angina and coronary artery spasm 1. However, the drug's mechanism as a calcium channel blocker that inhibits smooth muscle contraction 1 provides a theoretical basis for its use in rectal tenesmus.
Clinical Evidence
The evidence supporting diltiazem for tenesmus consists of:
Case series data only 2: A systematic review identified diltiazem among several pharmacological interventions studied for cancer-related rectal tenesmus, but noted substantial heterogeneity and lack of randomized controlled trials.
Two case reports 3: Both patients with malignancy-associated perineal pain and tenesmus experienced dramatic improvement in pressure-type pain and reduced opioid requirements after starting oral diltiazem. One patient described relief from pain "like sitting on a football."
Practical Application
When to consider diltiazem for tenesmus:
- Advanced cancer patients (colorectal, genitourinary, prostate) with rectal tenesmus
- Specifically when pain has a pressure-type quality rather than sharp or burning characteristics
- When surgery, radiotherapy, or chemotherapy are no longer options
- As an adjunct to opioids when pain control remains inadequate
Dosing approach:
- Start with oral diltiazem 120 mg daily (divided or long-acting formulation) 4
- Can titrate up to 360 mg daily as tolerated
Critical Precautions
Before prescribing diltiazem, exclude:
- Hypotension (diltiazem causes peripheral vasodilation and blood pressure reduction) 1
- Decompensated systolic heart failure or severe LV dysfunction 4
- AV block greater than first degree or SA node dysfunction without pacemaker 4
- Significant hepatic or renal dysfunction 4
Monitor for:
- Bradycardia and hypotension (most common adverse effects) 4
- Drug interactions—diltiazem is a CYP3A4 substrate and moderate inhibitor 4
Alternative Considerations
The systematic review 2 identified other interventions with similar limited evidence:
- Nifedipine (another calcium channel blocker)
- Methadone (may address both pain and smooth muscle effects)
- Local anesthetics (lidocaine, bupivacaine)
- Tricyclic antidepressants showed efficacy in rectal prolapse-associated tenesmus 5, though this is a different etiology
A multimodal approach is likely necessary given the complex pathophysiology of tenesmus involving smooth muscle spasm, inflammation, and neuropathic components 2.
Bottom Line
While diltiazem shows promise for malignancy-associated tenesmus with pressure-type characteristics, the evidence remains at the case series level. Given the palliative context where these patients present (advanced cancer, limited treatment options), a trial of diltiazem is reasonable when standard analgesics fail, provided cardiovascular contraindications are excluded. Start conservatively, monitor closely for hypotension and bradycardia, and use as part of a broader symptom management strategy rather than monotherapy.